Torrent Pharmaceuticals (TORNTPHARM) Stock Overview
Engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
TORNTPHARM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Torrent Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹3,548.30 |
| 52 Week High | ₹3,787.90 |
| 52 Week Low | ₹2,886.45 |
| Beta | 0.13 |
| 1 Month Change | -2.83% |
| 3 Month Change | 12.15% |
| 1 Year Change | 5.62% |
| 3 Year Change | 136.47% |
| 5 Year Change | 166.69% |
| Change since IPO | 29,469.17% |
Recent News & Updates
Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?
Aug 21
Torrent Pharmaceuticals Limited Just Missed EPS By 9.0%: Here's What Analysts Think Will Happen Next
Jul 31Pinning Down Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is Difficult Right Now
Jul 04Recent updates
Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?
Aug 21Torrent Pharmaceuticals Limited Just Missed EPS By 9.0%: Here's What Analysts Think Will Happen Next
Jul 31Pinning Down Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is Difficult Right Now
Jul 04Should You Be Adding Torrent Pharmaceuticals (NSE:TORNTPHARM) To Your Watchlist Today?
Jun 13Torrent Pharmaceuticals' (NSE:TORNTPHARM) Dividend Will Be ₹6.00
May 23We Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt With Ease
Mar 12Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Feb 19Torrent Pharmaceuticals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Jan 28If EPS Growth Is Important To You, Torrent Pharmaceuticals (NSE:TORNTPHARM) Presents An Opportunity
Dec 16Earnings Miss: Torrent Pharmaceuticals Limited Missed EPS By 7.7% And Analysts Are Revising Their Forecasts
Oct 29Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Popularity With Investors Is Under Threat From Overpricing
Oct 24Shareholder Returns
| TORNTPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.2% | 0.7% | 2.0% |
| 1Y | 5.6% | -6.2% | -5.4% |
Return vs Industry: TORNTPHARM exceeded the Indian Pharmaceuticals industry which returned -6.2% over the past year.
Return vs Market: TORNTPHARM exceeded the Indian Market which returned -5.4% over the past year.
Price Volatility
| TORNTPHARM volatility | |
|---|---|
| TORNTPHARM Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in IN Market | 8.0% |
| 10% least volatile stocks in IN Market | 3.3% |
Stable Share Price: TORNTPHARM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: TORNTPHARM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1959 | 17,059 | Aman Mehta | www.torrentpharma.com |
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services.
Torrent Pharmaceuticals Limited Fundamentals Summary
| TORNTPHARM fundamental statistics | |
|---|---|
| Market cap | ₹1.20t |
| Earnings (TTM) | ₹20.02b |
| Revenue (TTM) | ₹118.35b |
Is TORNTPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TORNTPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹118.35b |
| Cost of Revenue | ₹28.56b |
| Gross Profit | ₹89.79b |
| Other Expenses | ₹69.77b |
| Earnings | ₹20.02b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 59.16 |
| Gross Margin | 75.87% |
| Net Profit Margin | 16.92% |
| Debt/Equity Ratio | 42.8% |
How did TORNTPHARM perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/17 13:24 |
| End of Day Share Price | 2025/09/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Torrent Pharmaceuticals Limited is covered by 57 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Ashwin Mehta | Ambit Capital |
| Prashant Nair | Ambit Capital |